Therapeutic implication of human placental extract to prevent liver cirrhosis in rats with metabolic dysfunction-associated steatohepatitis
Clinical Science · 2024
DOI: 10.1042/cs20230533 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Science, 2024. Verfasst von Mitsuyoshi Yamagata und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology, Kanazawa Medical University, Uchinada, Ishikawa 920-0293, Japan. Hauptthemen laut MEDLINE: Placental Extracts, Fatty Liver, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 2.0). Gefördert von: Kanazawa Medical University.
Abstract (Originalsprache)
Metabolic dysfunction-associated steatohepatitis (MASH) is always accompanied with hepatic fibrosis that could potentially progress to liver cirrhosis and hepatocellular carcinoma. Employing a rat model, we evaluated the role of human placental extract (HPE) to arrest the progression of hepatic fibrosis to cirrhosis in patients with MASH. SHRSP5/Dmcr rats were fed with a high-fat and high-cholesterol diet for 4 weeks and evaluated for the development of steatosis. The animals were divided into control and treated groups and received either saline or HPE (3.6 ml/kg body weight) subcutaneously thrice a week. A set of animals were killed at the end of 6th, 8th, and 12th weeks from the beginning of the experiment. Serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), hepatic malondialdehyde (MDA), and glutathione content were measured. Immunohistochemical staining was performed for α-smooth muscle actin (α-SMA), 4-hydroxy-2-nonenal (4-HNE), collagen type I, and type III. Control rats depicted progression of liver fibrosis at 6 weeks, advanced fibrosis and bridging at 8 weeks, and cirrhosis at 12 weeks, which were significantly decreased in HPE-treated animals. Treatment with HPE maintained normal levels of MDA and glutathione in the liver. There was marked decrease in the staining intensity of α-SMA, 4-HNE, and collagen type I and type III in HPE treated rats compared with control animals. The results of the present study indicated that HPE treatment mediates immunotropic, anti-inflammatory, and antioxidant responses and attenuates hepatic fibrosis and early cirrhosis. HPE depicts therapeutic potential to arrest the progression of MASH towards cirrhosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatology, Kanazawa Medical University, Uchinada, Ishikawa 920-0293, Japan.
- Center for Regenerative Medicine, Kanazawa Medical University Hospital, Uchinada, Ishikawa 920-0293, Japan.
Förderung
- Kanazawa Medical University
Zitieren
APA
Yamagata, M., Tsuchishima, M., Saito, T., Tsutsumi, M., & George, J. (2024). Therapeutic implication of human placental extract to prevent liver cirrhosis in rats with metabolic dysfunction-associated steatohepatitis. Clinical Science. https://doi.org/10.1042/cs20230533
Vancouver
Yamagata M, Tsuchishima M, Saito T, Tsutsumi M, George J. Therapeutic implication of human placental extract to prevent liver cirrhosis in rats with metabolic dysfunction-associated steatohepatitis. Clinical Science. 2024. doi:10.1042/cs20230533
BibTeX
@article{Yamagata2024,
author = {Yamagata, Mitsuyoshi and Tsuchishima, Mutsumi and Saito, Takashi and Tsutsumi, Mikihiro and George, Joseph},
title = {Therapeutic implication of human placental extract to prevent liver cirrhosis in rats with metabolic dysfunction-associated steatohepatitis},
journal = {Clinical Science},
year = {2024},
doi = {10.1042/cs20230533}
}
EUVIMED